The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LX.g

Lymphomatoid granulomatosis (pulmonary, endothoracic)

Publications

Ichikawa S, Fukuhara N, Saito K, Onodera K, Shirai T, Onishi Y, Yokoyama H, Fujii H, Ichinohasama R, Harigae H

Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series.

International journal of hematology 2020 Jan 18;; — 2020 Jan 18

Watanabe H, Masuda R, Matsuzaki T, Hamanaka R, Ikoma Y, Nakano T, Oiwa K, Kohno M, Iwazaki M

A surgical case of methotrexate-associated lymphomatoid granuloma.

General thoracic and cardiovascular surgery 2018 Jul;66;435-438 — 2018 Jul — 435-438

Barakat A, Grover K, Peshin R

Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis.

SpringerPlus 2014;3;751 — 2014 — 751

Blanchart K, Paciencia M, Seguin A, Chantepie S, Du Cheyron D, Charbonneau P, Galateau-Salle F, Terzi N

Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis.

Minerva anestesiologica 2014 Jan;80;119-20 — 2014 Jan — 119-20

Kameda H, Okuyama A, Tamaru J, Itoyama S, Iizuka A, Takeuchi T

Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis.

Clinical rheumatology 2007 Sep;26;1585-9 — 2007 Sep — 1585-9